ClinicalTrials.gg
RecruitingNCT03399253Updated Jan 16, 2018

Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor

A Phase 2/3 interventional study of surgery and chemotherapy in Gastric Cancer, sponsored by Sun Yat-sen University. Recruiting at 9 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-01-16.

Sponsored by Sun Yat-sen University · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2022, 4 years ago, but the record still lists the study as recruiting.
  • Started Dec 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Stomach Neoplasms by Sun Yat-sen University — 6 open to participants now, 7 under way, 2 of them phase 3. Stomach Neoplasms · Sun Yat-sen University.

Planned enrollment
11th of 23
120 · median 110
Started
2017
with 2 others
Phase 2/3
Only one
of the 29
Registered
18th of 29
by date

Among the 29 studies in Stomach Neoplasms by Sun Yat-sen University, this one is the 11th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2017, is the only one in phase 2/3, and was the 18th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

6 of the 29 studies in Stomach Neoplasms by Sun Yat-sen University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Stomach Neoplasms by Sun Yat-sen University, or all of them as a file.
02

Study summary

Our study aims to compare the efficacy and safety of Chemotherapy Alone Versus D2 distal gastrectomy and metastasectomy plus Chemotherapy for gastric cancer (GC) with one non-curable Factor

Read the detailed description

Gastric cancer is the fourth most common malignancy worldwide and the second leading cause of cancer-related deaths, with the highest mortality rates reported in East Asia, including China. Many patients are diagnosed at an advanced stage of gastric cancer because of late onset and nonspecific symptoms. The prognosis of patients with advanced gastric cancer with non-curable factors, such as hepatic, peritoneal, or distant lymph node metastases, is poor. Chemotherapy is the standard of care for these patients. Palliative resection or bypass surgery is generally indicated in the presence of major symptoms such as bleeding or obstruction for incurable advanced gastric cancer. The usefulness of gastrectomy and metastasectomy is still unclear.

The REGATTA trial is the first clinical trial to explore the significance of surgery for incurable advanced gastric cancer. However, it concluded an opposite conclusion that gastrectomy followed by chemotherapy did not show any survival benefit compared with chemotherapy alone in advanced gastric cancer with a single non-curable factor. Interestingly, there was a significant interaction between treatment effect and tumor location in subgroup analyses of overall survival. Gastrectomy plus chemotherapy was associated with significantly worse overall survival in patients with upper-third tumors for less chemotherapy cycles. This finding raises the question whether inclusion criteria were restricted to the patients with lower-third tumor, findings of study might have been positive. So we raise this new trail to assess the significance of Gastrectomy and Metastasectomy for Distal Gastric Cancer With One Non-curable Factor.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • Distal Gastric Cancer, Gastrectomy, Metastasectomy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Lower age limit of research subjects 18 years old and upper age limit of 75 years old.
  2. PS () of 0 or 1.
  3. Without any other .
  4. Written from the patient.
  5. Standard gastrectomy with D2 lymphadenectomy for primary cancer
  6. A single non-curable factor was defined by preoperative CT :

    hepatic (H1 or H2; maximum diameter ≤4 cm, number ≤4); peritoneal metastasis (R0 or R1 resection) para-aortic lymph node metastasis (number ≤4) ovarian metastasis adrenal metastasis renal metastasis

  7. No to chemotherapy, including normal peripheral blood routine, liver and kidney function and (WBC≥4.0 x 109 /L, NEU≥1.5 x 109 /L,≥100 x 109 /L and HGB≥90g/L)

Exclusion criteria

Exclusion Criteria:

  1. Female in pregnancy or lactation.
  2. Supraclavicular lymph nodes ,lung and bone metastases.
  3. Massive ascites or cachexia.
  4. Extensive cancer metastases of liver, peritoneal metastasis,para-aortic lymph node
  5. Patients participating in any other clinical trails currently,or participated in other trails within 1 months.
  6. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases.
  7. Poor treatment compliance of patients
  8. The group of chemotherapy alone accepts gastrectomy for bleeding or obstruction
  9. Failure of R0 or R1 metastasectomy and gastrectomy with D2 lymphadenectomy
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Chemotherapy

    chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease

    Drug: chemotherapy

  • Experimental
    Surgery+Chemotherapy

    D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease

    Procedure: surgery · Drug: chemotherapy

Interventions

  • Proceduresurgery

    D2 gastrectomy + metastasectomy

  • Drugchemotherapy

    capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease

    Also known as: XELOX

06

What researchers measure

Primary outcomes

  1. Overall survival

    OS

    Time frame: 5-year

Secondary outcomes

  1. progression free survival

    PFS

    Time frame: 3-year

07

Study locations

9 of 9 sites recruiting
  • Anqing Municipal Hospital
    Anqing, Anhui, China
    Recruiting
    • Yaming Zhang · Contact
    • Daibin Tang · Contact13865176528
  • Anhui Provincial Hospital
    Hefei, Anhui, China
    Recruiting
    • Xuhui Zhao · Contact18963789289
    • Yifu He · Contact13485691976
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
    • Aman Xu · Contact13705695470
    • Fei Zhong · Contact18226616729
  • First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
    Recruiting
    • Lianghui Shi · Contact13956159006
  • Cancer Center of Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting
  • Yuebei People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
    • Tao Tao Zhang · Contact13500206389
  • Jiangxi Provincial Cancer Hospital
    Nanchang, Jiangxi, China
    Recruiting
    • Huamin Rao · Contact13879100685
  • Second Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang, China
    Recruiting
    • Li Chen · Contact13958092350
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, China
    Recruiting
    • Rupeng Zhang · Contact13920561244
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2017 (actual). Primary completion is estimated for Nov 2022, 58 months after the start.

Of 26 phase 2/3 interventional studies under Stomach Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's planned 58 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2018
First posted
Jan 16, 2018
StartActual
Dec 10, 2017
Primary completionEst.
Nov 1, 2022
CompletionEst.
Dec 1, 2025
Last update
Jan 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03399253
Responsible party
Dazhi Xu (professor, Sun Yat-sen University) — Principal investigator
First posted
Jan 16, 2018
Start date
Dec 10, 2017
Primary completion
Nov 1, 2022 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Jan 16, 2018

Study contacts

Dazhi Xu, PHD
Contact
xudzh@sysucc.org.cn
(+86) 020-87343737
Dazhi Xu, PHD
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion